The use of biomarkers holds great promise for the development of new therapeutics and the acceleration of clinical research. However, biomarkers must be validated — a complex and costly endeavor. Importantly, biomarker validation is meaningfully shaped by economic and policy-driven incentives.
Get full access to this article
View all access options for this article.
References
1.
S. P.Heyet al., “Challenges and Opportunities for Biomarker Validation,”Journal of Law, Medicine & Ethics47, no. 3 (2019): 357-361.
2.
R.Li and I.Sim, “How Clinical Trial Data Sharing Platforms Can Advance the Study of Biomarkers,”Journal of Law, Medicine & Ethics47, no. 3 (2019): 369-373; J.Shrageret al., “Is Cancer Solvable? Towards Efficient and Ethical Biomedical Science,”Journal of Law, Medicine & Ethics47, no. 3 (2019): 362-368.
3.
C.Mavergameset al., “Cochrane's Linked Data Project: How It can Advance Our Understanding of Surrogate Endpoints,”Journal of Law, Medicine & Ethics47, no. 3 (2019): 374-380; S. P.Heyet al., “Surrogate Endpoints and Drug Regulation: What is Needed to Clarify the Evidence,”Journal of Law, Medicine & Ethics47, no. 3 (2019): 381-387.
4.
A. D.Stern, B. M.Alexander, and A.Chandra, “Innovation Incentives and Biomarkers,”Clinical Pharmacology & Therapeutics103, no. 1 (2018): 34-36.
5.
A. D.Stern, B. M.Alexander, and A.Chandra, “How Economics can Shape Precision Medicines,”Science355, no. 6330 (2017): 1131-1133.
6.
D. B.Taichman, P.Sahni, A.Pinborg, L.Peiperl, C.Laine, A.James, S. T.Hong, A.Haileamlak, L.Gollogly, F.Godlee, and F. A.Frizelle, “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors,”JAMA317, no. 24 (2017): 2491-2492; R. M.Califf, D. A.Zarin, J. M.Kramer, R. E.Sherman, L. H.Aberle, and A.Tasneem, “Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010,”JAMA307, no. 17 (2012): 1838-1847.